The preparation of Ethyl 4-methyl-2-(4-(2-methylpropyloxy)-3-cyanophenyl)-5-thiazolecarboxylate is described in EP 0513379 wherein In the following route is described (Scheme-1):
Reaction of 4-hydroxy-3-nitrobenzaldehyde (II) with hydroxylamine and sodium formate in refluxing formic acid gives 4-hydroxy-3-nitrobenzonitrile(III), which is treated with thioacetamide to give corresponding thiobenzamide(IV). The cyclization of (IV) with 2-chloroacetoacid ethyl ester affords 2-(4-hydroxy-3-nitrophenyl)-4-methylthiozole-5-carboxylic acid ethyl ester(V), which is alkylated with isobutyl bromide providing the isobutyl ether(VI). The reduction of the Nitro-group of (VI) with H2 over Pd/C gives the amino derivative(VII), which is converted into Ethyl 4-methyl-2-(4-(2-methylpropyloxy)-3-cyanophenyl)-5-thiazolecarboxylate(I) by diazotization followed by and treatment with CuCN and KCN
The following are the drawbacks of the process:
Another route is disclosed in JP1994/345724 and in Heterocycles 1998, 47: 857-64. This route is illustrated by the following Scheme-2
The reaction of 4-nitrobenzonitrile(VIII) with KCN in DMSO in hot DMSO, followed by treatment with isobutyl bromide gives 4-isobutoxybenzene-1,3-dicarbonitrile(IX), which is treated with thioacetamide to yield 3-cyano-4-isobutoxythiobenzamide(X). Cyclization of (X) with 2-chloroacetoacitic acid ethyl ester affords Ethyl4-methyl-2-(4-(2-methylpropyloxy)-3-cyanophenyl)-5-thiazolecarboxylate(I)
Yet another process is described for the preparation of compound (I) in JP 1998/045733. This route can be illustrated by the following scheme-3
Cyclization of 4-hydroxythiobenzamide(XI) with 3-bromoacetoacetic acid ethyl ester provides 2-(4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester(XII), which is formylated by reaction with hexamethylenetetramine (HMTA) and polyphosphoric acid to afford 2-(3-formyl-4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester(XIII). Alkylation of (XIII) with isobutyl bromide gives 2-(3-formyl-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester(XIV), which is treated with formic acid, sodium formate and hydroxylamine hydrochloride to give Ethyl 4-methyl-2-(4-(2-methylpropyloxy)-3-cyanophenyl)-5-thiazolecarboxylate(I). Alternatively 2-(3-formyl-4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester(XIII) treated with formic acid, sodium formate and hydroxylamine hydrochloride to provide 2-(3-cyano-4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid(XV), which is treated with isobutyl bromide to give Ethyl 4-methyl-2-(4-(2-methylpropyloxy)-3-cyanophenyl)-5-thiazolecarboxylate(I)
It is very important to examine a process of preparing the compound of formula (I) from the point of industrial applicability whether the procedure fulfills the following requirements
All of the processes described above in the prior art do not fulfill one or other of the above conditions.
Further compound of formula (i) is the precursor of Febuxostat. As such, there is a need for compound of formula (I) of high purity which may be conveniently used as a precursor in the preparation of highly pure Febuxostat for therapeutic application.
Therefore we directed our R & D program to develop an improved process for the preparation of compound (I) taking into consideration the above mentioned requirements. The aim being to provide a new environmentally protective, safe, industrially viable process, which is devoid of the insufficiencies of the known procedures and makes possible the synthesis of compound (I) in high yields and purity.
Accordingly we directed our research based on the under mentioned points
Therefore the main object of the present invention is to provide an improved process for the preparation of highly pure (>99.0%) Febuxostat precursor Ethyl 4-methyl-2-(4-(2-methylpropyloxy)-3-cyanophenyl)-5-thiazolecarboxylate(I) hydrochloride avoiding the drawbacks of the hitherto known processes
Accordingly following scheme-4 illustrates salient aspects of the current invention.
Reaction of 3-bromo-4-hydroxy-benzaldehyde(XVI) with hydroxylamine hydrochloride and sodium formate in refluxing formic acid gives 3-bromo-4-hydroxy-benzonitrile (XVII). Treatment of the compound (XVII) with Thioacetamide gives 3-bromo-4-hydroxy-thiobenzamide(XVIII). Cyclization of compound (XVIII) with 2-chloroacetoacetic acid ethyl ester gives 2-(3-bromo-4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester(XIX). Alkylation of the compound (XIX) with isobutyl bromide gives 2-(3-bromo-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester(XX). Compound-XX on cyanation with cuprous cyanide gives Ethyl 4-methyl-2-(4-(2-methylpropyloxy)-3-cyanophenyl)-5-thiazolecarboxylate(I). Compound of formula-I is purified further by forming hydrochloride salt in acetone medium
Accordingly, the present invention provides process for the preparation of 3-bromo-4-hydroxy-benzonitrile (XVII) which comprises
Accordingly, the present invention provides process for the preparation of 3-bromo-4-hydroxy-thiobenzamide-(XVIII) which comprises
Accordingly, the present invention provides an improved method for the preparation of 2-(3-bromo-4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester(XIX) which comprises
Accordingly, the present invention provides an improved method for the preparation of 2-(3-bromo-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester(XX) which comprises
Accordingly, the present invention provides an improved method for the preparation of Ethyl 4-methyl-2-(4-(2-methylpropyloxy)-3-cyanophenyl)-5-thiazolecarboxylate(I) hydrochloride which comprises
Extracting with Ethyl acetate and washing Ethyl acetate layer with water
The solid state properties of Ethyl 4-methyl-2-(4-(2-methylpropyloxy)-3-cyanophenyl)-5-thiazolecarboxylate (I) as hydrochloride salt are illustrated by the following figures:
FIG. 1—XRPD spectrum of the hydrochloride salt of compound of the formula-I prepared by the method disclosed in example-1
FIG. 2—DSC curve of the hydrochloride salt of compound of the formula-I prepared by the method disclosed in example-1
FIG. 3—IR spectrum of the hydrochloride salt of compound of the formula-I prepared by the method disclosed in example-1
The details of the inventions are given in the Examples which are provided for illustration only and therefore the Examples should not be construed to limit the scope of the invention.
Into a 3 L round bottomed flask formic acid (98%, 0.7 L) and 3-bromo-4-hydroxy-benzaldehyde (100 g) were charged and stirred for 15 minutes. Sodium formate (59 g) and hydroxylamine hydrochloride (38.4 g) were charged and the reaction mixture was heated to 105-110° C. Reaction mass was maintained at the same temperature for 5 hours and brought to room temperature. Water (2.3 L) was added and the reaction mass was stirred for 2 hours. Reaction mass was filtered and washed with water (500 ml). Dried in tray drier at 60-65° C.
Yield: 69 g (70%)
Purity by HPLC: 97%
Melting range: 150-158° C.
Into a 3 L round bottomed flask a mixture of Isopropanolic hydrogen chloride (124 ml) and compound of formula-XVII (50 g) from the previous step were charged and stirred for 15 minutes. Thioacetamide (33.5 g) was charged and heated to 50-55° C. The reaction mass was maintained at the same temperature for 2 hour and water (330 ml) was added to the and stirred for 2 hours at 5-10° C. The product was filtered and dried at 50-60° C.
Yield: 43 g (75%)
Purity by HPLC: 95%
Melting range: 108-110° C.
Into a 1 L round bottomed flask Isopropanol (310 ml) and compound-XIII (40 g) from step-II were charged and stirred for 15 minutes. Ethyl-2-chloro aceto acetate (35.5 g) was charged and the reaction mass was heated to 80-85° C. and maintained at the same temperature for five hours. The reaction mass was brought to room temperature and maintained at the same temperature for 2 hours. The product was filtered and dried at 60-65° C.
Yield: 47 g (90%)
Purity by HPLC: 98.4%
Melting range: 204-210° C.
Into a 3 L round bottomed flask compound (XIX) from step-III (40 g) and dimethyl formamide (200 ml) were charged. Potassium carbonate (96.9 g) and isobutyl bromide (48.3 g) were added and the reaction mass was heated to 80-85° C. Reaction mass was maintained at the same temperature for five hours and brought to room temperature. Water (2 L) was charged to reaction mass and stirred for one hour. Reaction mass was filtered and washed with water (2×500 ml). The wet compound was dissolved in Ethyl acetate (1000 ml) and ethyl acetate layer was washed with water (400 ml×3). Ethyl acetate layer was dried over sodium sulphate and distilled off completely under vacuum. Methanol (240 ml) was added to the residue and heated to 50-55° C. and maintained at the same temperature for 15 minutes. Reaction mass was brought to room temperature and maintained for one hour. The compound (XX) was filtered and dried at 50-60° C.
Yield: 34 g (73.2%)
Purity by HPLC: 98%
Melting range: 108-109° C.
Into a 3 L round bottomed flask compound (XX) from step-IV (34 g) and dimethyl formamide (340 ml) were charged. Cuprous cyanide (13 g) and cuprous iodide (3.4 g) were added to reaction mass and heated to 130-140° C. The reaction mass was maintained at the same temperature for 16 hours, brought to room temperature and quenched into water (6.8 L). It was extracted with Ethyl acetate (3×750 ml) and the organic layer was washed with water (1.51×2). The organic layer was dried over sodium sulphate and the solvent was distilled off completely under vacuum. Ethyl acetate (155 ml) was added to the residue and cooled to 0-5° C. and maintained at the same temperature for 30 minutes. The reaction mass was filtered and recrystallized with n-butanol (700 ml). The compound-I was dried at 60-70° C. Yield: 22.5 g (98.5% by HPLC).
Compound of formula-I was suspended in acetone (660 ml) and heated to 50° C. and maintained at the same temperature for 15 minutes. Clear solution was brought to 30-35° C. and Concentrated hydrochloric acid (20 ml) was added slowly during 30 minutes. The reaction mass was cooled to 0-5° C. and filtered. The product was dried at 60-70° C.
Yield: 20 g (61.5%)
Purity by HPLC: 99.5%
Melting range: 170-173° C.
This hydrochloride salt can be directly taken for next hydrolysis step to get pharmaceutical grade Febuxostat.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/IN2010/000596 | 9/8/2010 | WO | 00 | 3/6/2013 |